Market Insight - Clinical trials metrics tell all about pharma's R&D investment
This article was originally published in Scrip
Executive Summary
When examining the competitiveness of company pipelines and the extent of firms' commitment to R&D, it is arguably more relevant to consider the number of drug projects as reflected by clinical trials' activity as opposed to the overall number of drugs in the pipeline. Using data from TrialTrove for the 12-month period from September 1st, 2008, to August 31st, 2009, where trial start dates were disclosed in the public domain, trial activity was analysed to determine overall rankings by industry sponsor and company R&D spend per trial.